Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study evaluating combination of Versamune MUC1 (formerly PDS0103)+ PDS01ADC to treat MUC1-positive progressive unresectable, metastatic colorectal carcinoma

Next Previous
Search
Trial Profile

A phase 1/2 study evaluating combination of Versamune MUC1 (formerly PDS0103)+ PDS01ADC to treat MUC1-positive progressive unresectable, metastatic colorectal carcinoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDS 0103 (Primary) ; PDS 0301 (Primary)
  • Indications Carcinoma; Colorectal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 28 Mar 2025 New trial record
    • 13 Mar 2025 According to a PDS Biotechnology Corporation media release, the USFDA has cleared the IND application for this study, filed by the company in January 2025. The National Cancer Institute (NCI), under its Cooperative Research and Development Agreement (CRADA) with PDS Biotech, will lead this Phase 1/2 clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top